CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Health By Reuters • October 5, 2026, 4:26 AM UTC
⏱ 1 min read 👁 1 views
Direct Source Verification: This story is aggregated from Reuters (reuters.com). Full reporting rights and copyright belong to the primary publisher.
Read on Reuters ↗
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis  Reuters
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis  Reuters
Original Source
https://www.reuters.com/business/healthcare-pharmaceuticals/csl-strikes-rare-disease-drug-deal-worth-up-16-billion-with-swiss-firm-alentis-2026-10-04/
Visit Reuters ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health